DiaMedica Therapeutics Inc. (DMAC) Financial Statements (2026 and earlier)

Company Profile

Business Address 301 CARLSON PARKWAY
MINNEAPOLIS, MN 55305
State of Incorp.
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:59,900,00055,300,00030,000,00037,300,00044,100,00050,200,000
Cash and cash equivalent15,647,0003,326,0004,109,0002,589,0003,025,0004,134,000
Short-term investments44,243,00051,992,00025,929,00033,731,00041,122,00046,063,000
Other undisclosed cash, cash equivalents, and short-term investments10,000(18,000)(38,000)980,000(47,000)3,000
Receivables258,000488,000303,000253,000236,000290,000
Deposits current assets  200,000200,000200,000  
Other undisclosed current assets471,000235,000576,000(331,000)274,000277,000
Total current assets:60,629,00056,223,00031,079,00037,422,00044,610,00050,767,000
Noncurrent Assets
Operating lease, right-of-use asset197,000218,000239,000259,000279,000298,000
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization145,000150,000152,000149,000148,000151,000
Long-term investments and receivables    1,000,000  
Long-term investments    1,000,000  
Deposits noncurrent assets     1,308,0001,308,000
Deferred costs400,000456,000    
Total noncurrent assets:742,000824,000391,0001,408,0001,735,0001,757,000
TOTAL ASSETS:61,371,00057,047,00031,470,00038,830,00046,345,00052,524,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5,020,0005,159,0004,008,0004,560,0005,287,0003,024,000
Accounts payable1,475,0001,920,0001,261,0001,507,000940,0001,171,000
Accrued liabilities3,545,0003,239,0002,747,0003,053,0004,347,0003,024,000
Other undisclosed accounts payable and accrued liabilities      (1,171,000)
Debt11,00010,00012,00012,00013,00014,000
Other undisclosed current liabilities101,00099,00096,00093,00090,0001,259,000
Total current liabilities:5,132,0005,268,0004,116,0004,665,0005,390,0004,297,000
Noncurrent Liabilities
Long-term debt and lease obligation4,0007,0008,00010,00012,00014,000
Finance lease, liability4,0007,0008,00010,00012,00014,000
Liabilities, other than long-term debt124,000150,000176,000201,000225,000249,000
Operating lease, liability124,000150,000176,000201,000225,000249,000
Total noncurrent liabilities:128,000157,000184,000211,000237,000263,000
Total liabilities:5,260,0005,425,0004,300,0004,876,0005,627,0004,560,000
Equity
Equity, attributable to parent56,111,00051,622,00027,170,00033,954,00040,718,00047,964,000
Additional paid in capital228,829,000215,600,000182,592,000181,658,000180,697,000179,985,000
Accumulated other comprehensive income (loss)50,00050,000(14,000)5,00023,00081,000
Accumulated deficit(172,768,000)(164,028,000)(155,408,000)(147,709,000)(140,002,000)(132,102,000)
Total equity:56,111,00051,622,00027,170,00033,954,00040,718,00047,964,000
TOTAL LIABILITIES AND EQUITY:61,371,00057,047,00031,470,00038,830,00046,345,00052,524,000

Income Statement (P&L) (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Operating expenses(9,213,000)(9,033,000)(8,007,000)(8,144,000)(8,419,000)(6,883,000)
Operating loss:(9,213,000)(9,033,000)(8,007,000)(8,144,000)(8,419,000)(6,883,000)
Nonoperating income483,000419,000314,000443,000528,000616,000
Investment income, nonoperating  440,000313,000   
Other nonoperating income (expense) (21,000)1,000443,000528,000616,000
Loss from continuing operations before income taxes:(8,730,000)(8,614,000)(7,693,000)(7,701,000)(7,891,000)(6,267,000)
Income tax expense(10,000)(6,000)(6,000)(6,000)(9,000)(7,000)
Net loss available to common stockholders, diluted:(8,740,000)(8,620,000)(7,699,000)(7,707,000)(7,900,000)(6,274,000)

Comprehensive Income (USD)

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net loss:(8,740,000)(8,620,000)(7,699,000)(7,707,000)(7,900,000)(6,274,000)
Comprehensive loss:(8,740,000)(8,620,000)(7,699,000)(7,707,000)(7,900,000)(6,274,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent 64,000(19,000)(18,000)(58,000)132,000
Comprehensive loss, net of tax, attributable to parent:(8,740,000)(8,556,000)(7,718,000)(7,725,000)(7,958,000)(6,142,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: